Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.